DJIA 17,698.18 -77.94 -0.44%
NASDAQ 4,880.23 -20.66 -0.42%
S&P 500 2,059.69 -8.20 -0.40%
market minute promo

4.33 -0.04 (-0.92%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ARNA $4.33 -0.92%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.35
Previous Close $4.37
Daily Range $4.15 - $4.37
52-Week Range $3.26 - $7.22
Market Cap $1.0B
P/E Ratio -15.61
Dividend (Yield) $0.00 (0.0%)
Volume 4,685,547
Average Daily Volume 5,278,661
Current FY EPS -$0.54

Sector

Healthcare

Industry

Drug Makers

Arena Pharmaceuticals, Inc. (ARNA) Description

A clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Website: http://www.arenapharm.com/

News & Commentary

Biotech Stocks: 2 to Avoid, 1 to Buy

Motley Fool contributor Todd Campbell offers insight on three biotech stocks, including two that investors should stay away from.

Arena - Assessing Belviq In South Korea

Orexigen Will Make The Obesity Space A Two-Product Race

Arena: Belviq Sales Flatter Than Needed - Q1 Revenue Miss Likely

Arena Investors Need To Pay Attention To Competition

ARNA Crosses Below Key Moving Average Level

Orexigen: Contrave Gathering Momentum

Vivus, Arena, Or Orexigen - Which Will Win The Anti-Obesity Market Share Race?

Orexigen - Contrave Scripts Up, Equity Down, Approval In Europe Still Not Announced

Arena: Belviq Scripts See Modest Rise, Revenue Story Not Promising

See More ARNA News...

ARNA's Top Competitors

ARNA $4.33 (-0.92%)
Current stock: ARNA
AMGN $157.10 (-1.72%)
Current stock: AMGN
GILD $97.72 (-0.42%)
Current stock: GILD
BIIB $413.81 (-2.00%)
Current stock: BIIB